Astria Therapeutics, Inc.

As of May 27, 2025, the market trend is mildly bearish, with daily indicators showing bearish sentiment while weekly signals suggest short-term strength, resulting in mixed signals across time frames.

As of March 2022, the management team of Astria Therapeutics, Inc. includes Independent Chairman Kenneth Bate, CEO and Co-Founder Dr. Jill Milne, and Independent Directors Dr. Burt Adelman, Dr. Joanne Beck, Mr. Hugh Cole, Mr. Michael Kishbauch, and Mr. Gregg Lapointe. They oversee the company's strategic direction and operations.

Astria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics, with a market cap of USD 321.68 million and a recent net profit of -34 million. The company has no dividend yield and negative financial metrics, including a debt equity ratio of -1.02 and a return on equity of -37.35%.

As of Jun 18, Astria Therapeutics, Inc. has a market capitalization of 321.68 million, with net sales of 0.00 million and a net profit of -108.04 million over the latest four quarters. Shareholder's funds are 319.26 million, and total assets amount to 342.36 million.